ZNL 02-096 is a potent and selective Wee1 Degrader (PROTAC™) that comprises the Wee1 inhibitor AZD 1775 joined by a linker to the cereblon-binding ligand Pomalidomide (Cat. No. 6302). ZNL 02-096 selectively degrades Wee1 at submicromolar concentrations, while sparing PLK1, an AZD 1775 secondary target. In MOLT-4 cells
in vitro
, ZNL 02-096 induces degradation of Wee1, accumulation of DNA damage, arrest of the cell cycle in the G2/M phase and apoptosis. The compound shows antiproliferative effects in a panel of 300 cancer cell lines.
PROTAC™ is a registered trademark of Arvinas Operations, Inc., and is used under license.
Caractéristiques techniques
| Marque | Tocris Bioscience |
|---|
| Réf. B-LABO | BL-RE-151536 |
|---|
| Réf. fabricant | 18738776 |
|---|
| Nom chimique ou matériau | 4-((3-(4-(4-((2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-3-oxo-2,3-dihydro-1 H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)phenyl)piperazin-1-yl)propyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione |
|---|
| CAS | 2414418-49-6 |
|---|
| Quantité | 1 mg |
|---|
| Cible | Active Degraders |
|---|
| Formule moléculaire | C<sub>42</sub>H<sub>45</sub>N<sub>11</sub>O<sub>6</sub> |
|---|
| Pureté | 0.98 |
|---|
Une question, une configuration particulière ?
Contactez-nous pour un devis.
